Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Not yet recruiting
Immunocore Ltd
Phase 2
2024-06-30
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201
positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an
integrated circulating tumor DNA (ctDNA) biomarker.
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Not yet recruiting
Diwakar Davar
Phase 2
2024-06-30
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201
positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an
integrated circulating tumor DNA (ctDNA) biomarker.
This phase II trial tests how well tebentafusp works to shrink tumors prior to primary treatment with surgery or radiation in patients with uveal (eye) melanoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Tebentafusp is a drug that binds to melanoma tumor cells as well as immune cells called T-cells. This binding causes an immune response against the melanoma cells, which leads to tumor cell death. Tebentafusp has been approved for the treatment of locally advanced and unresectable uveal melanoma. Giving tebentafusp before primary treatment with surgery or radiation may help shrink the tumor, prevent the disease from spreading, or reduce the likelihood that patients will require total eye removal (called enucleation).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
